Certara (CERT) Stock
Drug discovery software and consulting for pharmaceutical companies. Here's the price, business snapshot, and what's worth knowing about Certara in August 2026.
Certara Inc (CERT) provides software and consulting services that use pharmacological modelling and simulation to support drug discovery and development. Its platforms help pharmaceutical and biotech companies design trials, predict dosing and accelerate regulatory submissions. With a market capitalisation of about $1.97 billion, Certara combines recurring subscription revenue from software with professional services and royalties. Investors often watch its revenue growth, gross margins and progress integrating acquisitions that broaden its modelling capabilities. Opportunities centre on the wider adoption of model-informed drug development and rising R&D spend, but there are risks: exposure to pharmaceutical budgets, competitive technologies, and execution on product development and integration. Financial performance can be variable and past trends don’t guarantee future returns. This summary is educational only and not personal investment advice; investors should assess suitability for their own circumstances and consider professional advice where appropriate.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Certara's stock with a target price of $12.16, indicating good growth potential.
Financial Health
Certara is successfully generating solid revenue and cash flow, showing good profitability and financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Model‑Informed Development
Certara’s modelling platforms can reduce trial time and cost, a theme investors may find interesting — though outcomes can vary with execution and adoption.
Recurring Revenue Mix
Subscription software plus services offer recurring revenue potential, but margins depend on scale, pricing and successful integration of acquisitions.
Sector Tailwinds
Growing R&D spend and regulatory interest in simulation support long‑term demand, yet sensitivity to pharma budgets and competition adds uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
